Literature DB >> 20576292

Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample.

Luis Gutiérrez-Rojas1, Dolores Jurado, José María Martínez-Ortega, Manuel Gurpegui.   

Abstract

BACKGROUND: We analyzed the association of previous course-of-illness and other variables of clinical interest with a high frequency of both depressive or (hypo)manic episodes controlling for the effect of socio-demographic characteristics.
METHODS: A total of 108 outpatients with a DSM-IV diagnosis of bipolar disorder (BD) were recruited. A retrospective and naturalistic study was conducted to examine the number of affective episodes and their relationship with socio-demographic, clinical and course-of-illness variables, including adherence to medication, type of medication used and the use of addictive substances. The episode frequency was estimated as the number of "major instances" of depression, hypomania and mania during the illness. To classify the patients into two groups (higher and lower-episode frequency), we used the statistical criterion of median split. Results were analyzed with logistic regression models to control for the effects of potential confounders.
RESULTS: A high episode frequency (nine or more episodes) was associated with age (36-55years), delay in diagnosis, poor adherence to medication and current use of antipsychotic medication. In addition, a high frequency of manic episodes (four or more) was associated with female sex, age (>36years) and a manic onset of the illness, whereas a high frequency of depressive episodes (five or more) was associated with delay in diagnosis and poor adherence to medication. LIMITATIONS: Cross-sectional study design.
CONCLUSIONS: Avoiding delay in diagnosis and enhancing treatment adherence might be important targets for reducing recurrences in BD.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20576292     DOI: 10.1016/j.jad.2010.05.021

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  14 in total

1.  Seasonality, smoking and history of poor treatment compliance are strong predictors of dropout in a naturalistic 6 year follow-up of bipolar patients.

Authors:  Elena Ezquiaga; Aurelio García-López; Consuelo de Dios; Jose Luis Agud; David Albillo; Lorena Vega-Piris
Journal:  Psychiatr Q       Date:  2014-12

2.  Does the efficacy of asenapine in bipolar disorder increase in the presence of comorbidity with a substance use disorder? A naturalistic study.

Authors:  Sergio De Filippis; Ilaria Cuomo; Georgios D Kotzalidis; Daniela Pucci; Pietro Zingaretti; Raffaella Porrari; Camilla Fini; Paola Motta; Matteo Caloro; Paolo Girardi
Journal:  Ther Adv Psychopharmacol       Date:  2016-10-28

3.  Facilitators and Barriers of Medication Adherence Based on Beliefs of Persons with Bipolar Disorder: A Qualitative Study.

Authors:  Jose Ángel Alcalá; Andrés Fontalba-Navas; Miguel Company-Morales; Samuel L Romero-Guillena; Teófilo Gutiérrez-Higueras; Luis Gutiérrez-Rojas
Journal:  Int J Environ Res Public Health       Date:  2022-06-22       Impact factor: 4.614

4.  Depressive residual symptoms are associated with illness course characteristics in a sample of outpatients with bipolar disorder.

Authors:  Gianluca Serafini; Gustavo H Vazquez; Xenia Gonda; Maurizio Pompili; Zoltan Rihmer; Mario Amore
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-02-07       Impact factor: 5.270

5.  Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder.

Authors:  Jodi M Gonzalez; Peter M Thompson; Troy A Moore
Journal:  Patient Prefer Adherence       Date:  2011-07-01       Impact factor: 2.711

6.  Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms.

Authors:  Wayne Macfadden; Caleb M Adler; Ibrahim Turkoz; John T Haskins; Norris Turner; Larry Alphs
Journal:  BMC Psychiatry       Date:  2011-10-28       Impact factor: 3.630

7.  Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.

Authors:  Pierre Michel Llorca; Mocrane Abbar; Philippe Courtet; Sebastien Guillaume; Sylvie Lancrenon; Ludovic Samalin
Journal:  BMC Psychiatry       Date:  2013-12-20       Impact factor: 3.630

8.  A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder.

Authors:  Yuan Hwa Chou; Po-Chung Chu; Szu-Wei Wu; Jen-Chin Lee; Yi-Hsuan Lee; I-Wen Sun; Chen-Lin Chang; Chien-Liang Huang; I-Chao Liu; Chia-Fen Tsai; Yung-Chieh Yen
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-08-31       Impact factor: 2.582

9.  Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials.

Authors:  Taro Kishi; Kazuto Oya; Nakao Iwata
Journal:  Int J Neuropsychopharmacol       Date:  2016-09-21       Impact factor: 5.176

10.  Patterns of persistence with pharmacological treatment among patients with current depressive episode and their impact on long-term outcome: a naturalistic study with 5-year follow-up.

Authors:  Kanglai Li; Jiong Tao; Yuemei Li; Minhua Chen; Xiuhua Wu; Yingtao Liao; Xiaolan Lin; Zhaoyu Gan
Journal:  Patient Prefer Adherence       Date:  2018-05-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.